- 0207 299 0388
- Weekday Hours: 10AM - 5PM
*In some cases, if the doctor requires more information, you may be asked to answer follow-up questions or attend a 1-to-1 virtual consultation before a prescription is approved
*In some cases, if the doctor requires more information, you may be asked to answer follow-up questions or attend a 1-to-1 virtual consultation before a prescription is approved
One of the most prevalent adverse effects of perimenopause and menopause, affecting at least 50% of women, is weight gain. Research from the SWAN and Healthy Women’s studies indicates that women gain roughly 1.5 kg annually throughout perimenopause, adding up to an average weight gain of 10kg by the time they approach menopause.
One of the most prevalent adverse effects of perimenopause and menopause, affecting at least 50% of women, is weight gain. Research from the SWAN and Healthy Women’s studies indicates that women gain roughly 1.5 kg annually throughout perimenopause, adding up to an average weight gain of 10kg by the time they approach menopause.
Semaglutide may be useful in managing menopausal weight gain, according to
studies. Patients on semaglutide who took a weekly dose of 2.4 mg for 68
weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their
body weight, compared to 2.4% for the placebo group.
Semaglutide may be useful in managing menopausal weight gain, according to
studies. Patients on semaglutide who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group.
Semaglutide, a medication for type 2 diabetes, is marketed under the name Wegovy. Semaglutide are members of the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. These drugs imitate the functions of the GLP-1 hormone, which aids in controlling body weight, food consumption, and hunger. By slowing down the time it takes to digest the food consumed, it makes the person feel fuller for longer which in turn reduces food intake. This accompanied with a healthy lifestyle will lead to successful weight loss outcomes.
Semaglutide may be useful in managing menopausal weight gain, according to studies.
Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months,
dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the
placebo group. People who took Ozempic in conjunction with good lifestyle practices like
exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different
research done by Novo Nordisk, the company that makes semaglutide.
Semaglutide may be useful in managing menopausal weight gain, according to studies. Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group. People who took Ozempic in conjunction with good lifestyle practices like exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different research done by Novo Nordisk, the company that makes semaglutide.
Read our articles on Wegovy & Mounjaro if you would like to learn more about the benefits, the research and case studies.
Yes, you can get Wegovy prescribed by a doctor during menopause. Wegovy can manage weight gain, improve insulin sensitivity, and reduce abdominal fat, which are common issues in menopause. It is important to note that Wegovy is not a hormonal therapy and does not treat menopausal symptoms.
Studies have shown that Wegovy has significantly reduced visceral fat, which increases after menopause and increases the metabolic risk. Improving insulin sensitivity and promoting fat loss, it helps shift body composition toward lower central fat and better metabolic health.
Wegovy is not a hormone therapy; it does not treat hot flashes or mood changes caused by low oestrogen. However, many women may feel better emotionally and experience improved energy and confidence as their weight and metabolic health improve while on Wegovy.
Menopause can increase insulin resistance due to oestrogen decline and fat redistribution. Semaglutide enhances insulin sensitivity by reducing the production of glucose by the liver, slows down the gastric emptying, and promotes weight loss.
Menopause accelerates sarcopenia. When Wegovy is combined with resistance training and adequate protein intake, it may preserve muscle loss. Nutrition and exercise remain essential alongside the medication to maintain metabolic rate and bone strength.
Wegovy improves metabolic control, and weight reduction can enhance sleep quality, reduce snoring, and improve daytime energy levels. Wegovy does not directly treat insomnia or fatigue related to hormonal fluctuations. Combining it with sleep hygiene and hormonal evaluations gives the best results.
Wegovy does not increase oestrogen levels or affect hormone production. It works through the GLP-1 pathway to control appetite and blood sugar.
Wegovy cannot reverse menopause or restore oestrogen production. It helps with weight loss and metabolic health, but has no effect on ovarian function or the natural hormonal changes of menopause.
Weight regain is common after stopping the medication if lifestyle changes are not followed. The medication helps control appetite while in use, so continuing healthy eating, exercise and behaviour habits is important.
Wegovy can slow digestion, which may slightly affect the absorption of oral hormonal replacement therapy. However, other methods like patches, gels, or sprays are usually unaffected. Always inform your doctor if you are on hormone replacement therapy so they can adjust the form or dose if needed.
Book an Appointment Today
Sign-up using your e-mail to regularly receive useful
& interesting weight loss information!
By clicking signup you agree to our Privacy Policy and Terms of Use
All consultations and prescriptions are carried out by GMC registered medical practitioners.
All dispensing and shipping of medicines are completed by a UK licensed, GPhC registered Pharmacy no: 9011284.
CloudRx is our partner pharmacy and prescribing service.
*Disclaimer: Results may vary from person to person depending on individual engagement and commitment to the programme.
The content of this website is provided for general informational purposes only and is not intended as, nor should it be considered a substitute for, professional medical advice. Do not use the information on this website for diagnosing or treating any medical or health related condition. If you have or suspect you have a medical problem, promptly contact your healthcare provider.
© 2025 The London Obesity Clinic
